The study’s outcome measures include pain intensity (Visual Analogue Scale), functional impairment (Back Performance Scale and Oswestry Disability Index), golf-specific performance indicators (clubhead speed and shot distance), and biochemical liver and kidney parameters.
Conditions
Interventions
Group 1: Participants receive cannabidiol (CBD) in the specified dosage. After a washout period, they cross over to the placebo condition.
Group 2: Participants receive a placebo matching the CBD prep
Sponsors
Deutsche Sporthochschule Köln
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Participants must be golfers aged 50 years or older with medically confirmed chronic back pain (persisting for at least three months), a regular golfing activity for at least one year, and possession of a valid golf proficiency certificate (Platzreife).
Exclusion criteria
Exclusion criteria: Individuals will be excluded if they do not provide written informed consent, present with impaired liver or kidney function, have an acute disc prolapse or manifest osteoporosis, suffer from severe physical or psychiatric disorders, or are currently taking pain medication. Additional exclusion criteria include acute infections and known hypersensitivity to any of the administered substances (CBD or placebo).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome: Change in pain intensity, functional impairment, and golf-specific performance variables after administration of cannabidiol (CBD) compared to placebo in recreational golfers with chronic lower back pain. Assessment Time Points: T0 = Screening / pre-assessment (eligibility check, informed consent, baseline demographics), T1 = Baseline before the first intervention phase (CBD or placebo, randomized), T2 = After 7 days of the first intervention phase, T3 = Baseline before the second intervention phase (cross-over), T4 = After 7 days of the second intervention phase. A 4-week wash-out period is implemented between T2 and T3. Measurement Instruments: Pain intensity: Visual Analogue Scale (VAS) Functional impairment: Oswestry Disability Index (ODI) Functional mobility: Back Performance Scale (BPS) Golf-specific performance: Clubhead speed and shot distance measured with FlightScope (3D Doppler radar technology) Physiological Parameters: Analysis of liver and kidney function parameters as well as CBD concentrations in blood to verify CBD intake and identify potential adverse effects (assessed at T1–T4). | — |
Secondary
| Measure | Time frame |
|---|---|
| The planned study aims to address the following research questions: What is the effect of CBD administration on pain intensity (Visual Analogue Scale) in recreational golfers? What is the effect of CBD administration on spinal mobility during daily activities (Back Performance Scale) in recreational golfers? What is the effect of CBD administration on functional impairment (Oswestry Disability Index) in recreational golfers? What is the effect of CBD administration on swing performance variables (clubhead speed and shot distance) in recreational golfers? What potential health risks are associated with CBD administration in relation to liver and kidney parameters in the blood of recreational golfers? | — |
Countries
Germany
Contacts
Public ContactBianca Werdelmann
Deusche Sporthochschule Köln
Outcome results
None listed